JP2010520883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520883A5 JP2010520883A5 JP2009552910A JP2009552910A JP2010520883A5 JP 2010520883 A5 JP2010520883 A5 JP 2010520883A5 JP 2009552910 A JP2009552910 A JP 2009552910A JP 2009552910 A JP2009552910 A JP 2009552910A JP 2010520883 A5 JP2010520883 A5 JP 2010520883A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- chloro
- diazepin
- compound
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 208000037976 chronic inflammation Diseases 0.000 claims description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 5
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- IIPUDAGCAJCTJT-UHFFFAOYSA-N 1-[4-[3-[(2-bromophenyl)methyl]-7-chloro-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-(2,2,2-trifluoroethyl)urea Chemical compound C1=CC(NC(=O)NCC(F)(F)F)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Br IIPUDAGCAJCTJT-UHFFFAOYSA-N 0.000 claims description 2
- NMVPSAGRKCQZAO-UHFFFAOYSA-N 1-[4-[3-[(2-bromophenyl)methyl]-7-chloro-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-(2-ethoxyethyl)urea Chemical compound C1=CC(NC(=O)NCCOCC)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Br NMVPSAGRKCQZAO-UHFFFAOYSA-N 0.000 claims description 2
- USKLYLPLUIQWAE-UHFFFAOYSA-N 1-[4-[3-[(2-bromophenyl)methyl]-7-chloro-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-(2-methoxyethyl)urea Chemical compound C1=CC(NC(=O)NCCOC)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Br USKLYLPLUIQWAE-UHFFFAOYSA-N 0.000 claims description 2
- HCKMKLZNSAJPHB-UHFFFAOYSA-N 1-[4-[3-[(2-bromophenyl)methyl]-7-chloro-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-[2-(dimethylamino)ethyl]urea Chemical compound C1=CC(NC(=O)NCCN(C)C)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Br HCKMKLZNSAJPHB-UHFFFAOYSA-N 0.000 claims description 2
- RVCIYVSHZIOGRJ-UHFFFAOYSA-N 1-[4-[3-[(2-bromophenyl)methyl]-7-chloro-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-cyclopropylurea Chemical compound N1=C(C=2C=CC(NC(=O)NC3CC3)=CC=2)C2=CC(Cl)=CC=C2NC(=O)C1CC1=CC=CC=C1Br RVCIYVSHZIOGRJ-UHFFFAOYSA-N 0.000 claims description 2
- UPOUEZGGMHDDLU-UHFFFAOYSA-N 1-[4-[3-[(2-bromophenyl)methyl]-7-chloro-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-methylurea Chemical compound C1=CC(NC(=O)NC)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Br UPOUEZGGMHDDLU-UHFFFAOYSA-N 0.000 claims description 2
- RKEJHLBRBBLNGU-UHFFFAOYSA-N 1-[4-[3-[(2-bromophenyl)methyl]-7-chloro-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-propan-2-ylurea Chemical compound C1=CC(NC(=O)NC(C)C)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Br RKEJHLBRBBLNGU-UHFFFAOYSA-N 0.000 claims description 2
- IYEWOSIFWULNJW-UHFFFAOYSA-N 1-[4-[7-chloro-2-oxo-3-[[2-(trifluoromethyl)phenyl]methyl]-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-propan-2-ylurea Chemical compound C1=CC(NC(=O)NC(C)C)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1C(F)(F)F IYEWOSIFWULNJW-UHFFFAOYSA-N 0.000 claims description 2
- RILPJCZZSPPAFK-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-chlorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-(2,2,2-trifluoroethyl)urea Chemical compound C1=CC(NC(=O)NCC(F)(F)F)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Cl RILPJCZZSPPAFK-UHFFFAOYSA-N 0.000 claims description 2
- AWCBPHDNEGSDOS-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-chlorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-(2-ethoxyethyl)urea Chemical compound C1=CC(NC(=O)NCCOCC)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Cl AWCBPHDNEGSDOS-UHFFFAOYSA-N 0.000 claims description 2
- QBXAKSGMQRBMBA-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-chlorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-(2-methoxyethyl)urea Chemical compound C1=CC(NC(=O)NCCOC)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Cl QBXAKSGMQRBMBA-UHFFFAOYSA-N 0.000 claims description 2
- AZFRGWONNFCVRF-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-chlorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-[2-(dimethylamino)ethyl]urea Chemical compound C1=CC(NC(=O)NCCN(C)C)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Cl AZFRGWONNFCVRF-UHFFFAOYSA-N 0.000 claims description 2
- BCBRDNOCFGVWAJ-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-chlorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-cyclopropylurea Chemical compound N1=C(C=2C=CC(NC(=O)NC3CC3)=CC=2)C2=CC(Cl)=CC=C2NC(=O)C1CC1=CC=CC=C1Cl BCBRDNOCFGVWAJ-UHFFFAOYSA-N 0.000 claims description 2
- XQGKJKRNVYTZEM-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-chlorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-methylurea Chemical compound C1=CC(NC(=O)NC)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Cl XQGKJKRNVYTZEM-UHFFFAOYSA-N 0.000 claims description 2
- YRCGSLGQXMMZBM-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-chlorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-propan-2-ylurea Chemical compound C1=CC(NC(=O)NC(C)C)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Cl YRCGSLGQXMMZBM-UHFFFAOYSA-N 0.000 claims description 2
- WTNMIAIEWNPWTJ-UHFFFAOYSA-N 1-[4-[7-chloro-3-[(2-fluorophenyl)methyl]-2-oxo-1,3-dihydro-1,4-benzodiazepin-5-yl]phenyl]-3-propan-2-ylurea Chemical compound C1=CC(NC(=O)NC(C)C)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1F WTNMIAIEWNPWTJ-UHFFFAOYSA-N 0.000 claims description 2
- RMYPRFPKXOHANH-UHFFFAOYSA-N 3-[(2-bromophenyl)methyl]-7-chloro-1-methyl-5-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=C3NC(=O)NC3=CC=2)=NC1CC1=CC=CC=C1Br RMYPRFPKXOHANH-UHFFFAOYSA-N 0.000 claims description 2
- APNWNPCBUGCQDM-UHFFFAOYSA-N 3-[(2-bromophenyl)methyl]-7-chloro-5-(4-hydroxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(O)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Br APNWNPCBUGCQDM-UHFFFAOYSA-N 0.000 claims description 2
- BHEIEROWUGRDAE-UHFFFAOYSA-N 3-[(3-bromophenyl)methyl]-7-chloro-5-(4-hydroxyphenyl)-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=CC(Br)=C1 BHEIEROWUGRDAE-UHFFFAOYSA-N 0.000 claims description 2
- XTSXGBWEVIYXHY-UHFFFAOYSA-N 3-[(4-bromophenyl)methyl]-7-chloro-5-(4-hydroxyphenyl)-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=C(Br)C=C1 XTSXGBWEVIYXHY-UHFFFAOYSA-N 0.000 claims description 2
- -1 4-ethylbenzyl Chemical group 0.000 claims description 2
- YYQYFWOSIYYOMC-UHFFFAOYSA-N 7-chloro-1-methyl-5-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=C3NC(=O)NC3=CC=2)=NC1CC1=CC=CC=C1C(F)(F)F YYQYFWOSIYYOMC-UHFFFAOYSA-N 0.000 claims description 2
- XZJYPOHRBGVXAI-UHFFFAOYSA-N 7-chloro-3-[(2-chlorophenyl)methyl]-1-methyl-5-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=C3NC(=O)NC3=CC=2)=NC1CC1=CC=CC=C1Cl XZJYPOHRBGVXAI-UHFFFAOYSA-N 0.000 claims description 2
- ZGZVMAWYHZQCRZ-UHFFFAOYSA-N 7-chloro-3-[(2-chlorophenyl)methyl]-5-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=C3NC(=O)NC3=CC=2)C2=CC(Cl)=CC=C2NC(=O)C1CC1=CC=CC=C1Cl ZGZVMAWYHZQCRZ-UHFFFAOYSA-N 0.000 claims description 2
- JTBVZGDNQXYPCR-UHFFFAOYSA-N 7-chloro-3-[(2-chlorophenyl)methyl]-5-(4-hydroxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(O)=CC=C1C(C1=CC(Cl)=CC=C1NC1=O)=NC1CC1=CC=CC=C1Cl JTBVZGDNQXYPCR-UHFFFAOYSA-N 0.000 claims description 2
- UVCHKOCUFMZNNB-UHFFFAOYSA-N 7-chloro-3-[(2-chlorophenyl)methyl]-5-(4-hydroxyphenyl)-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=CC=C1Cl UVCHKOCUFMZNNB-UHFFFAOYSA-N 0.000 claims description 2
- PVUVANBISCVCOM-UHFFFAOYSA-N 7-chloro-3-[(2-ethylphenyl)methyl]-5-(4-hydroxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound CCC1=CC=CC=C1CC1C(=O)NC2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 PVUVANBISCVCOM-UHFFFAOYSA-N 0.000 claims description 2
- WPYWLRHNKPPWEU-UHFFFAOYSA-N 7-chloro-3-[(2-ethylphenyl)methyl]-5-(4-hydroxyphenyl)-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound CCC1=CC=CC=C1CC1C(=O)N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 WPYWLRHNKPPWEU-UHFFFAOYSA-N 0.000 claims description 2
- OZVCPHZRQFZEPC-UHFFFAOYSA-N 7-chloro-3-[(3-chlorophenyl)methyl]-5-(4-hydroxyphenyl)-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=CC(Cl)=C1 OZVCPHZRQFZEPC-UHFFFAOYSA-N 0.000 claims description 2
- YPAAOOCDZWKTEU-UHFFFAOYSA-N 7-chloro-3-[(3-ethylphenyl)methyl]-5-(4-hydroxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound CCC1=CC=CC(CC2C(NC3=CC=C(Cl)C=C3C(C=3C=CC(O)=CC=3)=N2)=O)=C1 YPAAOOCDZWKTEU-UHFFFAOYSA-N 0.000 claims description 2
- YVCRFYMQQAMLID-UHFFFAOYSA-N 7-chloro-3-[(3-ethylphenyl)methyl]-5-(4-hydroxyphenyl)-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound CCC1=CC=CC(CC2C(N(C)C3=CC=C(Cl)C=C3C(C=3C=CC(O)=CC=3)=N2)=O)=C1 YVCRFYMQQAMLID-UHFFFAOYSA-N 0.000 claims description 2
- CIBBQTOJJGTKSM-UHFFFAOYSA-N 7-chloro-3-[(4-ethylphenyl)methyl]-5-(4-hydroxyphenyl)-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound C1=CC(CC)=CC=C1CC1C(=O)N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 CIBBQTOJJGTKSM-UHFFFAOYSA-N 0.000 claims description 2
- AGKQFJGZZBWCLE-UHFFFAOYSA-N 7-chloro-5-(2-oxo-1,3-dihydrobenzimidazol-5-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound FC(F)(F)C1=CC=CC=C1CC1C(=O)NC2=CC=C(Cl)C=C2C(C=2C=C3NC(=O)NC3=CC=2)=N1 AGKQFJGZZBWCLE-UHFFFAOYSA-N 0.000 claims description 2
- HRERBCNMDASXRB-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-[(2-methylphenyl)methyl]-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=CC=C1C HRERBCNMDASXRB-UHFFFAOYSA-N 0.000 claims description 2
- KQQDGGVZYWABFP-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-[(3-methylphenyl)methyl]-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=CC(C)=C1 KQQDGGVZYWABFP-UHFFFAOYSA-N 0.000 claims description 2
- HTZZWVDRLYDVIG-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-[(3-propan-2-ylphenyl)methyl]-3H-1,4-benzodiazepin-2-one Chemical compound CC(C)C1=CC=CC(CC2C(N(C)C3=CC=C(Cl)C=C3C(C=3C=CC(O)=CC=3)=N2)=O)=C1 HTZZWVDRLYDVIG-UHFFFAOYSA-N 0.000 claims description 2
- QNRAEQBQEZHFAT-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-[(4-methylphenyl)methyl]-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=C(C)C=C1 QNRAEQBQEZHFAT-UHFFFAOYSA-N 0.000 claims description 2
- DNHFEIXHDNENEF-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-[(4-propan-2-ylphenyl)methyl]-3H-1,4-benzodiazepin-2-one Chemical compound C1=CC(C(C)C)=CC=C1CC1C(=O)N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 DNHFEIXHDNENEF-UHFFFAOYSA-N 0.000 claims description 2
- XXZXKAGVVMTDKS-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-[[2-(trifluoromethyl)phenyl]methyl]-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=CC=C1C(F)(F)F XXZXKAGVVMTDKS-UHFFFAOYSA-N 0.000 claims description 2
- SDIKDRVKXGQSCM-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-[[4-(trifluoromethyl)phenyl]methyl]-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(C)C2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=NC1CC1=CC=C(C(F)(F)F)C=C1 SDIKDRVKXGQSCM-UHFFFAOYSA-N 0.000 claims description 2
- GSBGGYFOSSNZKL-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-3-[(2-methylphenyl)methyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound CC1=CC=CC=C1CC1C(=O)NC2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 GSBGGYFOSSNZKL-UHFFFAOYSA-N 0.000 claims description 2
- VECQLNUIFNOSHI-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-3-[(3-methylphenyl)methyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound CC1=CC=CC(CC2C(NC3=CC=C(Cl)C=C3C(C=3C=CC(O)=CC=3)=N2)=O)=C1 VECQLNUIFNOSHI-UHFFFAOYSA-N 0.000 claims description 2
- ZEUSPHSDGABHNA-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-3-[(4-methylphenyl)methyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(C)=CC=C1CC1C(=O)NC2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 ZEUSPHSDGABHNA-UHFFFAOYSA-N 0.000 claims description 2
- JGDQTZXGZQVIQK-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-3-[(4-propan-2-ylphenyl)methyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(C(C)C)=CC=C1CC1C(=O)NC2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 JGDQTZXGZQVIQK-UHFFFAOYSA-N 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- IQZCYXHKTNGZAR-UHFFFAOYSA-N 7-chloro-5-(4-hydroxyphenyl)-3-[(3-propan-2-ylphenyl)methyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound CC(C)C1=CC=CC(CC2C(NC3=CC=C(Cl)C=C3C(C=3C=CC(O)=CC=3)=N2)=O)=C1 IQZCYXHKTNGZAR-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- IMWPTMNUGJACFZ-UHFFFAOYSA-N 7-chloro-3-[(4-ethylphenyl)methyl]-5-(4-hydroxyphenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(CC)=CC=C1CC1C(=O)NC2=CC=C(Cl)C=C2C(C=2C=CC(O)=CC=2)=N1 IMWPTMNUGJACFZ-UHFFFAOYSA-N 0.000 description 1
- INSBDBXZODXJRB-UHFFFAOYSA-N CC(C)(C)Cc1cccc(CC2N=C(c(cc3N4)ccc3NC4=O)c3cc(Cl)ccc3NC2=O)c1 Chemical compound CC(C)(C)Cc1cccc(CC2N=C(c(cc3N4)ccc3NC4=O)c3cc(Cl)ccc3NC2=O)c1 INSBDBXZODXJRB-UHFFFAOYSA-N 0.000 description 1
- XTOBCZIECREQLT-UHFFFAOYSA-N CC(C)(C)NC(Nc(cc1)ccc1C(c1cc(Cl)ccc1N1)=NC(Cc2ccccc2)C1=O)=O Chemical compound CC(C)(C)NC(Nc(cc1)ccc1C(c1cc(Cl)ccc1N1)=NC(Cc2ccccc2)C1=O)=O XTOBCZIECREQLT-UHFFFAOYSA-N 0.000 description 1
- HFUUBRRWUHHOFT-UHFFFAOYSA-N CC(C)C1=CC=CC(CC2N=CC(C=CC=C3)=C3N(C(C=C3)=CC=C3O)C2=O)=C1 Chemical compound CC(C)C1=CC=CC(CC2N=CC(C=CC=C3)=C3N(C(C=C3)=CC=C3O)C2=O)=C1 HFUUBRRWUHHOFT-UHFFFAOYSA-N 0.000 description 1
- XAXAIVVFSMMIHN-UHFFFAOYSA-N CC(C)Cc1ccc(CC2N=C(c(cc3N4)ccc3NC4=O)c(cc(cc3)Cl)c3NC2=O)cc1 Chemical compound CC(C)Cc1ccc(CC2N=C(c(cc3N4)ccc3NC4=O)c(cc(cc3)Cl)c3NC2=O)cc1 XAXAIVVFSMMIHN-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90601607P | 2007-03-09 | 2007-03-09 | |
| US60/906,016 | 2007-03-09 | ||
| PCT/US2008/056231 WO2008112553A1 (en) | 2007-03-09 | 2008-03-07 | Compositions and methods relating to novel compounds and targets thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010520883A JP2010520883A (ja) | 2010-06-17 |
| JP2010520883A5 true JP2010520883A5 (enExample) | 2011-04-21 |
| JP5383513B2 JP5383513B2 (ja) | 2014-01-08 |
Family
ID=39759934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552910A Expired - Fee Related JP5383513B2 (ja) | 2007-03-09 | 2008-03-07 | 化合物およびその標的に関連する組成物ならびに方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7851465B2 (enExample) |
| EP (1) | EP2139331B1 (enExample) |
| JP (1) | JP5383513B2 (enExample) |
| KR (1) | KR101164718B1 (enExample) |
| CN (1) | CN101662940A (enExample) |
| AU (1) | AU2008226532B2 (enExample) |
| BR (1) | BRPI0808653A2 (enExample) |
| CA (2) | CA2680017C (enExample) |
| MX (1) | MX2009009645A (enExample) |
| NZ (1) | NZ579507A (enExample) |
| WO (1) | WO2008112553A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7144880B2 (en) * | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
| US20060025388A1 (en) * | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
| MXPA01011052A (es) | 1999-04-30 | 2002-11-22 | Univ Michigan | Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas. |
| US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| CA2611031A1 (en) * | 2005-06-01 | 2007-05-10 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
| US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
| CA2779041A1 (en) * | 2005-11-01 | 2007-05-10 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
| US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
| JP5264716B2 (ja) * | 2006-06-09 | 2013-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物および方法 |
| JP5383513B2 (ja) * | 2007-03-09 | 2014-01-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物ならびに方法 |
| NZ583689A (en) * | 2007-09-14 | 2012-04-27 | Univ Michigan | F1f0-atpase inhibitors and related methods |
| NZ584842A (en) | 2007-11-06 | 2012-06-29 | Univ Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions, in particular, psoriasis |
| AU2009291632B2 (en) | 2008-09-11 | 2013-04-04 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
| WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| JP2013505258A (ja) | 2009-09-18 | 2013-02-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ベンゾジアゼピノン化合物およびそれを使用する治療方法 |
| US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| JP5856064B2 (ja) | 2009-11-17 | 2016-02-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物 |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| US20150111973A1 (en) * | 2012-03-13 | 2015-04-23 | Novan, Inc. | Methods of modulating steroid hormone activity |
| US20150182490A1 (en) | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| CN103724207B (zh) * | 2013-12-20 | 2016-07-06 | 北京智博高科生物技术有限公司 | 苯基苄基醚类衍生物及其制备方法和应用 |
| US11537690B2 (en) | 2019-05-07 | 2022-12-27 | The Nielsen Company (Us), Llc | End-point media watermarking |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU11248A1 (ru) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Способ очистки антрацена |
| FR900482A (fr) | 1942-12-17 | 1945-06-29 | Fides Gmbh | Condensateur électrostatique avec diélectrique consistant au moins partiellement en produits de transformation non conducteurs d'une armature |
| US2457405A (en) | 1945-09-25 | 1948-12-28 | Monsanto Chemicals | Halo nitroparaffin modified aminoplasts |
| FR66979E (fr) | 1953-06-22 | 1957-11-04 | Glaenzer Spicer Sa | Support pour arbre rotatif |
| US3374264A (en) | 1962-10-04 | 1968-03-19 | Hoffmann La Roche | N-haloacetyl-anthranilic acids and esters |
| US3261828A (en) | 1962-10-04 | 1966-07-19 | Hoffmann La Roche | 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds |
| US3384635A (en) | 1966-09-28 | 1968-05-21 | Sterling Drug Inc | 1, 4-benzodiazepine derivatives |
| US3415814A (en) | 1966-09-28 | 1968-12-10 | Sterling Drug Inc | 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione |
| AT280290B (de) | 1967-11-24 | 1970-04-10 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen 1-Phenyl-4-alkyl-3H-1,4-benzodiazepin-2,5-[1H,4H]-dionen |
| US4108852A (en) | 1969-03-18 | 1978-08-22 | Knoll Ag. | Process for preparing 1,5-benzodiazepine-2-ones |
| USRE30293E (en) | 1969-03-18 | 1980-06-03 | Knoll A.G. | Process for preparing 1,5-benzodiazepine-2-ones |
| GB1363735A (en) | 1970-10-23 | 1974-08-14 | Hoechst Ag | Process for the manufacture of benzimidazolones |
| GB1324469A (en) | 1970-10-28 | 1973-07-25 | Knoll Ag | Derivatives of benzodiazepines |
| ZA7464B (en) | 1973-01-16 | 1974-11-27 | J Voorhees | Treatment of proliferating skin diseases with papavine alkaloids |
| IE38931B1 (en) | 1973-03-09 | 1978-07-05 | Lipha | Triazolobenzodiazepines |
| US4076823A (en) | 1977-08-18 | 1978-02-28 | E. R. Squibb & Sons, Inc. | Triazolo-2,4-benzodiazepines |
| US4495101A (en) | 1983-04-28 | 1985-01-22 | American Home Products Corporation | Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives |
| US4551480A (en) | 1983-06-21 | 1985-11-05 | Stiefel Laboratories, Inc. | Compositions for the treatment of psoriasis |
| US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| US4820834A (en) | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
| US5004741A (en) | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
| DE3435974A1 (de) | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung |
| FR2591596B1 (fr) | 1985-12-13 | 1988-09-09 | Roussel Uclaf | Nouvelles 4h-triazolo(4,3-a)(1,4)benzodiazepines, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4751223A (en) | 1986-10-14 | 1988-06-14 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines |
| US4898861A (en) | 1987-03-26 | 1990-02-06 | Hoffmann-La Roche Inc. | Method for inhibiting the proliferation of tumor cells |
| US5147872A (en) | 1987-06-09 | 1992-09-15 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically psoriasis |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4970207A (en) | 1988-07-07 | 1990-11-13 | Fujisawa Pharmaceutical Company, Ltd. | Benzodiazepine derivatives |
| SE8804074D0 (sv) | 1988-11-10 | 1988-11-10 | Pharmacia Ab | Sensorenhet och dess anvaendning i biosensorsystem |
| US5501959A (en) | 1989-01-17 | 1996-03-26 | Alamar Biosciences Laboratory, Inc. | Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| US5258510A (en) | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| US5041438A (en) | 1989-10-30 | 1991-08-20 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with benzodiazepine compounds |
| US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
| EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| ATE145208T1 (de) | 1990-07-06 | 1996-11-15 | Yoshitomi Pharmaceutical | Kondensierte thiophenverbindungen und deren verwendung |
| BR9200951A (pt) | 1991-03-21 | 1992-11-17 | Hoffmann La Roche | Compostos, processo para sua producao,preparacoes farmaceuticas e uso |
| JPH07504908A (ja) | 1992-03-16 | 1995-06-01 | メルク シヤープ エンド ドーム リミテツド | ベンゾジアゼピン誘導体，該誘導体を含有する組成物及び治療におけるその使用 |
| US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| US5391566A (en) | 1993-07-20 | 1995-02-21 | Merck & Co., Inc. | Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives |
| AU692916B2 (en) * | 1993-11-22 | 1998-06-18 | Merck & Co., Inc. | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4- benzodiazepines |
| US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| US5444092A (en) | 1994-07-20 | 1995-08-22 | Collins; Jerry | Method and composition for treating psoriasis |
| JPH10504545A (ja) | 1994-07-29 | 1998-05-06 | 藤沢薬品工業株式会社 | ベンゾジアゼピン誘導体 |
| US5618792A (en) | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
| US5677282A (en) | 1995-06-07 | 1997-10-14 | Proscript, Inc. | Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase |
| US5962337A (en) | 1995-06-29 | 1999-10-05 | Pharmacopeia, Inc. | Combinatorial 1,4-benzodiazepin-2,5-dione library |
| RU2096044C1 (ru) | 1995-07-19 | 1997-11-20 | Малое предприятие "Ветта" | Ветеринарный имплантируемый препарат для регулирования биологического ритма животных |
| US5776946A (en) | 1995-08-28 | 1998-07-07 | Mcgeer; Patrick L. | Peripheral benzodiazepine receptor ligands as antiinflammatory agents |
| US6004942A (en) | 1995-08-30 | 1999-12-21 | The Regents Of The University Of California | Methods for treating arthritis by administering an apoptosis regulator |
| US5929069A (en) | 1995-09-21 | 1999-07-27 | Institute Of Medicinal Molecular Design, Inc. | Compounds activating pharmacological effects of retinoids |
| US6579854B1 (en) | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
| US7351421B2 (en) | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
| JP3999819B2 (ja) | 1996-12-10 | 2007-10-31 | ゼリア新薬工業株式会社 | １，５―ベンゾジアセピン誘導体 |
| US6074859A (en) | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
| US6080568A (en) | 1997-08-19 | 2000-06-27 | Genencor International, Inc. | Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis |
| DE69832984T2 (de) | 1997-10-08 | 2006-09-21 | Isotechnika, Inc., Edmonton | DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| US6206914B1 (en) | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
| FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US20030044776A1 (en) | 1998-09-25 | 2003-03-06 | James A. Dykens | Compositions and methods for identifying agents that alter mitochondrial permeability transition pores |
| FR2785803B1 (fr) | 1998-11-17 | 2005-03-25 | Sanofi Sa | Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes |
| US7175953B2 (en) | 1999-04-09 | 2007-02-13 | Institute Fuer Diagnostik Forschung | Short-warp peptide-dye conjugate as contrast agent for optical diagnostic |
| US7144880B2 (en) | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
| MXPA01011052A (es) * | 1999-04-30 | 2002-11-22 | Univ Michigan | Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas. |
| US7276348B2 (en) * | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
| US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
| US20050113460A1 (en) | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US20030119029A1 (en) | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| US20040176358A1 (en) | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| WO2001004103A1 (en) | 1999-07-13 | 2001-01-18 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
| US6524623B1 (en) | 1999-11-12 | 2003-02-25 | Milton Hodosh | Therapeutic compositions and methods of use thereof |
| AU2001255709A1 (en) | 2000-05-11 | 2001-11-20 | Eastman Chemical Company | Acylated cyclodextrin guest inclusion complexes |
| US20020048566A1 (en) | 2000-09-14 | 2002-04-25 | El-Deiry Wafik S. | Modulation of cellular apoptosis and methods for treating cancer |
| AU2002231098A1 (en) | 2000-12-15 | 2002-06-24 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| JP2005503356A (ja) | 2001-06-07 | 2005-02-03 | ニューロ３デー | 環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用 |
| AU2002332560B2 (en) | 2001-08-15 | 2006-01-19 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| WO2003050261A2 (en) | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| WO2003106628A2 (en) | 2002-06-17 | 2003-12-24 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase |
| US7150433B2 (en) | 2002-08-16 | 2006-12-19 | Toyota Motor Sales, U.S.A., Inc. | Aircraft bolster trays |
| US20040087489A1 (en) | 2002-11-06 | 2004-05-06 | Antonio Ruiz | Compositions and methods for the treatment of mycobacterial infections |
| US7745431B2 (en) * | 2002-12-03 | 2010-06-29 | Vela Acquisition Corporation | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof |
| ATE440827T1 (de) | 2002-12-04 | 2009-09-15 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
| AU2004255153B2 (en) | 2003-05-01 | 2007-11-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| US20050272723A1 (en) | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| AU2005262322B2 (en) | 2004-07-01 | 2012-07-26 | Synta Pharmaceuticals Corp. | 2-substituted heteroaryl compounds |
| US20060052369A1 (en) | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| WO2006053193A2 (en) | 2004-11-10 | 2006-05-18 | Garden Guardian, Inc. | A device and method for controlling animal behavior |
| JP2008528448A (ja) | 2005-01-03 | 2008-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 新規化合物に関連する組成物および方法、ならびにその標的 |
| CA2611031A1 (en) | 2005-06-01 | 2007-05-10 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
| EP1742460A1 (en) | 2005-06-18 | 2007-01-10 | TTE Germany GmbH | Raster distortion correction circuit |
| US20070105844A1 (en) | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
| CA2627757A1 (en) | 2005-10-26 | 2007-05-03 | The Regents Of The University Of Michigan | Therapeutic compositions and methods |
| CA2779041A1 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
| US7759338B2 (en) | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
| JP5264716B2 (ja) | 2006-06-09 | 2013-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物および方法 |
| GB0615068D0 (en) | 2006-07-28 | 2006-09-06 | Ttp Communications Ltd | Digital radio systems |
| JP5383513B2 (ja) | 2007-03-09 | 2014-01-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物ならびに方法 |
| NZ583689A (en) | 2007-09-14 | 2012-04-27 | Univ Michigan | F1f0-atpase inhibitors and related methods |
| NZ584842A (en) | 2007-11-06 | 2012-06-29 | Univ Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions, in particular, psoriasis |
-
2008
- 2008-03-07 JP JP2009552910A patent/JP5383513B2/ja not_active Expired - Fee Related
- 2008-03-07 EP EP08731682A patent/EP2139331B1/en active Active
- 2008-03-07 CA CA2680017A patent/CA2680017C/en not_active Expired - Fee Related
- 2008-03-07 NZ NZ579507A patent/NZ579507A/en not_active IP Right Cessation
- 2008-03-07 BR BRPI0808653-2A patent/BRPI0808653A2/pt not_active IP Right Cessation
- 2008-03-07 US US12/044,589 patent/US7851465B2/en not_active Expired - Fee Related
- 2008-03-07 CN CN200880012931A patent/CN101662940A/zh active Pending
- 2008-03-07 CA CA2783589A patent/CA2783589A1/en not_active Abandoned
- 2008-03-07 WO PCT/US2008/056231 patent/WO2008112553A1/en not_active Ceased
- 2008-03-07 MX MX2009009645A patent/MX2009009645A/es active IP Right Grant
- 2008-03-07 KR KR1020097021092A patent/KR101164718B1/ko not_active Expired - Fee Related
- 2008-03-07 AU AU2008226532A patent/AU2008226532B2/en not_active Ceased
-
2010
- 2010-12-07 US US12/962,225 patent/US8242109B2/en not_active Expired - Fee Related
-
2012
- 2012-07-10 US US13/545,546 patent/US20120289498A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1151789C (zh) | 芳基(或杂芳基)吡咯基甲醇的衍生物的应用 | |
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| FI4098256T3 (fi) | Annosteluohjelma s1p-reseptorin agonistille | |
| MA31396B1 (fr) | Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes | |
| MX2009001962A (es) | Acilanilidas substituidas y metodos de uso de las mismas. | |
| JP2021175759A (ja) | 認知機能を改善するための方法および組成物 | |
| DE60018274D1 (de) | Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden | |
| JP2011502958A5 (enExample) | ||
| KR20100130596A (ko) | 부신 피질 자극 호르몬 방출 인자 길항 작용을 갖는 3 환식 화합물 및 이를 함유하는 약학 조성물 | |
| AU2008321353A1 (en) | Methods for treating visceral pain | |
| RU2012101095A (ru) | Диарилтиогидантоиновые соединения | |
| JP2025516005A5 (enExample) | ||
| US11419857B2 (en) | Methods and compositions for treating pain | |
| JP2008538578A (ja) | 疼痛の治療 | |
| JP2007509960A5 (enExample) | ||
| JP2010539091A5 (enExample) | ||
| US7759346B2 (en) | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | |
| JP2006500315A5 (enExample) | ||
| EA023728B1 (ru) | Терапевтическое средство от тревожных расстройств | |
| JP2017514884A (ja) | 医療用の（ｒ）−ピルリンドールおよびその薬学的に許容可能な塩 | |
| EA202090205A1 (ru) | Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов | |
| JP2008519080A5 (enExample) | ||
| SI2303264T1 (en) | Methods for treating alpha-adrenergic mediated states using imidazoline derivatives | |
| US20220047608A1 (en) | Method of Treatment and Pharmaceutical Composition for Morning Hypertension | |
| WO2004082686A2 (en) | Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction |